Supercharged immune cells take on stubborn esophageal cancer

NCT ID NCT07622940

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new treatment for advanced esophageal cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that are designed to recognize and attack cancer cells carrying two specific proteins (CLDN18.2 and HER2). Up to 36 adults will receive the cells along with chemotherapy to prepare the body. The main goals are to check safety and find the right dose, while also looking for signs that tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: engineered immune cells (CAR-NK cells) targeting CLDN18.2 and HER2 proteins, plus chemotherapy drugs fludarabine and cyclophosphamide
What this could lead to: If it works, this could point toward a new treatment option for advanced esophageal cancer that has stopped responding to standard therapies.
What could go wrong: This is an early phase 1/2 trial with only 36 participants, so results are preliminary. The treatment may not shrink tumors or could cause serious side effects like immune reactions or organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOMARKER-SELECTED CLDN18.2-POSITIVE AND/OR HER2-POSITIVE DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenocarcinoma Of Esophagus esophageal adenocarcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOMARKER-SELECTED CLDN18.2-POSITIVE AND/OR HER2-POSITIVE DISEASE RECURRENT OR METASTATIC ESOPHAGEAL ADENOCARCINOMA

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.